(Albany, US) DelveInsight has launched a new report on “Hypertriglyceridemia Pipeline Insights, 2020”.
“Hypertriglyceridemia Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hypertriglyceridemia market. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided, which includes the disease overview and Hypertriglyceridemia treatment guidelines.
The assessment part of the report embraces in-depth Hypertriglyceridemia commercial assessment and clinical assessment of the Hypertriglyceridemia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Some of the Companies:
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight
Drugs Covered:
Scope of the Report
Hypertriglyceridemia refers to a fasting plasma triglyceride measurement that is increased, typically above the 95th percentile for age and sex along with additional quantitative or qualitative lipoprotein abnormalities. Patients can fluctuate between hypertriglyceridemic states: given appropriate metabolic stress, mild or moderate hypertriglyceridemia can deteriorate into severe hypertriglyceridemia.
The two main sources of plasma triglycerides (also known as triacylglycerol) are exogenous (i.e., from dietary fat)— carried in chylomicrons, and endogenous (from the liver)—carried in very-low-density lipoprotein (VLDL) particles.
HTG can be divided into primary and secondary types. In primary HTG, chylomicrons normally are cleared rapidly from plasma by lipoprotein lipase with apolipoprotein (apo) C-II as a cofactor—familial chylomicronemia (hyperlipoproteinemia type 1, in the Fredrickson system) and primary mixed hyperlipidemia (type 5) are each characterized by the pathologic presence of chylomicrons after a 12–14 h period of fasting—whereas, in secondary HTG, obesity is probably the metabolic stressor most frequently associated with hypertriglyceridemia, although associations with poorly controlled type 2 diabetes and excessive alcohol consumption are also common (associated with a secondary cause/acquired).
Table of Contents:
1. Report Introduction
2. Hypertriglyceridemia
3. Hypertriglyceridemia Current Treatment Patterns
4. Hypertriglyceridemia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Hypertriglyceridemia Late Stage Products (Phase-III)
7. Hypertriglyceridemia Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hypertriglyceridemia Discontinued Products
13. Hypertriglyceridemia Product Profiles
14. Hypertriglyceridemia Key Companies
15. Hypertriglyceridemia Key Products
16. Dormant and Discontinued Products
17. Hypertriglyceridemia Unmet Needs
18. Hypertriglyceridemia Future Perspectives
19. Hypertriglyceridemia Analyst Review
20. Appendix
21. Report Methodology
Request for Detailed TOC: https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight
Key Questions
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight